Clinical Trial

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Name: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN — clinical trial record (NCT06690827)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.

Trial Details

NCT Number	NCT06690827
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Enrollment	30 participants
Start Date	2024-11-13
Primary Completion	2027-10-30 (estimated)
Study Completion	2028-10-30 (estimated)
Updated on ClinicalTrials.gov	2024-11-15